Mogroside III

Mogroside III is a triterpenoid glycoside. Mogroside III exhibits maltase inhibitory effect with an IC₅₀ value of 1.6 mM. Mogroside III enhances oocyte developmental potential by promoting autophagy in cumulus cells. Mogroside III, as the active ingredient of the low-polarity glycoside component (L-SGgly), L-SGgly can increase serum GLP-1 levels, improve insulin resistance, and reduce IL-6 levels, and has hypoglycemic, lipid-regulating and anti-inflammatory effects. Mogroside III can be used for the studies of type 2 diabetes mellitus (T2DM) and assisted reproductive technology^[1][2][3]. In Vitro:Mogroside III (12.5-50 μM, 24 h) enhances oocyte in vitro maturation (IVM) and subsequent developmental potential^[2].
Mogroside III (25 μM, 24 h) induces upregulation of autophagy-related genes and proteins in cumulus cells (CCs), leading to WT1 degradation and increases FSHR expression, which in turn promotes estrogen and progesterone secretion and improves oocyte quality^[2].
In Vivo:Mogroside III (20 mg/kg low-polar Siraitia grosvenorii glycosides, content 5.5%, i.g., once daily for 14 days) exhibits anti-hyperglycemic and anti-hyperlipidemic effects on obese T2DM rats^[1].